The phenomenon of psycho-active drugs, and our reactions to them, is one of the most fascinating topics of the social history of mankind. Starting with an analysis of the 'policy of fear' in which law enforcement is 'haunted' by drug money, Drugs and Money offers a radical reconsideration of this highly contentious issue. In this intriguing book, Petrus C. van Duyne and Michael Levi expose an ever-unfolding series of problems: the proliferation of mind-influencing substances the complications of international drug regulation the interaction between markets and economic actors, with the consequent amassing of huge amounts of crime-money. The social, cultural and economic aspects of this crime-money are explored, alongside the ongoing threat it poses to the legitimate economy and the state.
In the last thirty years, the big pharmaceutical companies have transformed themselves into marketing machines selling dangerous medicines as if they were Coca-Cola or Cadillacs. They pitch drugs with video games and soft cuddly toys for children; promote them in churches and subways, at NASCAR races and state fairs. They've become experts at promoting fear of disease, just so they can sell us hope. No question: drugs can save lives. But the relentless marketing that has enriched corporate executives and sent stock prices soaring has come with a dark side. Prescription pills taken as directed by physicians are estimated to kill one American every five minutes. And that figure doesn't reflect the damage done as the overmedicated take to the roads. Our Daily Meds connects the dots for the first time to show how corporate salesmanship has triumphed over science inside the biggest pharmaceutical companies and, in turn, how this promotion driven industry has taken over the practice of medicine and is changing American life. It is an ageless story of the battle between good and evil, with potentially life-changing consequences for everyone, not just the 65 percent of Americans who unscrew a prescription cap every day. An industry with the promise to help so many is now leaving a legacy of needless harm.
An eminent scientist talks about the pharmaceutical industry, biotechnology and the future of drug research. In the course of our busy, technologically-driven lives, it is taken for granted that we respond to minor fluctuations in our health by taking pills -- pills for headache and for toothache; sleeping pills and tranquilizers; pills to lower fever, quiet coughs, and clear the sinuses; medicines to reduce appetite; preparations to relieve heartburn; and many more. In the war against serious disease, medicines are an indispensable weapon in the physician's arsenal: they save lives, or at least prolong them and make them more bearable. Despite the important role that pharmaceuticals play in our lives, few of us know where medicines come from or how the pharmaceutical industry discovers and develops new drugs. Jurgen Drews, an acclaimed leader in the pharmaceutical industry, tells the fascinating story of drug discovery and development from his years of successfully leading internatnional research teams at Hoffman-LaRoche. Drews traces the history of modern drug development from pharmacies, chemical companies, and individual entrepeneurs in Switzerland, Germany and the U.S. to the mega-corporations that dot the landscape of Europe, Japan and America. He describes the process by which new drugs are tested and brought to market, including a provacative look at how AIDS activism stimulated the approval process in the US. Drews' commentary on the role of clinical trials -- the time involved and their cost -- is sobering testimony to the complexity of bringing innovation to the marketplace. In the final two chapters of "In Quest of Tomorrow's Medicines", Drews offers an important and critical analysis of research in the the pharmaceutical industry, pointing to strategies that work and management practices that impede progress. Drews' comments on the impact that the growing relationship between the biotechnology industry and university-sponsored research will have ont he pharmaceutical industry makes provocative reading for pharmaceutical researchers, managers and investors. "In Quest of Tomorrow's Medicines" in written in clear, thoughtful language for people in the pharmaceutical and biotechnology industries, as well as policy makers, industry analysts and observers.
Examining the issue of 'British decline' after the war, this fascinating text describes the evolution of cooperation in Britain and France, and argues that the relationship between these two countries helped to disseminate a culture of research, resulting in the transformation of the medical sciences and the pharmaceutical industry in both countries. Of interest to a wide range of academic disciplines, this highly relevant book discusses topics including penicillin, sulphamide drugs, and the effects of war in both countries.